Technical Analysis for GRAY - Graybug Vision, Inc.

Grade Last Price % Change Price Change
F 4.75 -10.88% -0.58
GRAY closed down 10.88 percent on Monday, April 12, 2021, on 1.79 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Very Strong N/A Down Down
Historical GRAY trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -10.88%
Narrow Range Bar Range Contraction -10.88%
NR7 Range Contraction -10.88%
Older End-of-Day Signals for GRAY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 10% about 4 hours ago
Trending on StockTwits about 7 hours ago
60 Minute Opening Range Breakdown about 7 hours ago
1.5x Volume Pace about 7 hours ago
Down 5% about 7 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Graybug Vision, Inc. Description

Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Diseases Macular Degeneration Ophthalmology Related Macular Degeneration Retina Glaucoma Nerve Diabetic Retinopathy Macular Edema Blindness Wet Age Related Macular Degeneration Diabetic Macular Edema Retinopathy Intravitreal Administration Macula Of Retina Intravitreal Injection

Is GRAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 37.88
52 Week Low 4.62
Average Volume 618,281
200-Day Moving Average 0.00
50-Day Moving Average 16.13
20-Day Moving Average 6.35
10-Day Moving Average 5.47
Average True Range 0.91
ADX 63.93
+DI 8.32
-DI 40.84
Chandelier Exit (Long, 3 ATRs ) 5.99
Chandelier Exit (Short, 3 ATRs ) 7.35
Upper Bollinger Band 8.52
Lower Bollinger Band 4.18
Percent B (%b) 0.13
BandWidth 68.36
MACD Line -2.82
MACD Signal Line -3.39
MACD Histogram 0.5669
Fundamentals Value
Market Cap 99.65 Million
Num Shares 21 Million
EPS
Price-to-Sales 0.00
Price-to-Book 5.44
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.81
Resistance 3 (R3) 5.88 5.60 5.63
Resistance 2 (R2) 5.60 5.33 5.57 5.57
Resistance 1 (R1) 5.18 5.17 5.04 5.10 5.51
Pivot Point 4.90 4.90 4.83 4.86 4.90
Support 1 (S1) 4.47 4.63 4.33 4.40 3.99
Support 2 (S2) 4.19 4.46 4.16 3.93
Support 3 (S3) 3.77 4.19 3.87
Support 4 (S4) 3.69